For example, preliminary data that informed the rationale for the Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK-D) trial suggested treatment with spironolactone positively impacted left ventricular function, mass and aortic stiffness in people with CKD stages 2 and 3 who were already established on treatment with an ACEi or ARB20,21. This evidence concerns the gene NR3C2 and chronic kidney disease.